AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 283 min read$BHC

Revenue has grown for 14 straight quarters at Bausch Health, excluding Bausch + Lomb.

Bausch Health reported Q3 2026 revenues of $2.94B, up 10% YoY, with adjusted EBITDA growth of 32%. Excluding Bausch + Lomb, revenue grew 12% and adjusted EBITDA grew 32%. The company raised full-year guidance for revenue, adjusted EBITDA, and adjusted cash flows. Bausch Health also announced a share repurchase program.

Original reporting
stocktitan.net
Published Oct 28, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BHC
Bullish
high confidence
Mentioned
$BHC
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings release provides fresh revenue and EBITDA numbers and an upward revision to full‑year guidance, which can move the stock.

02

Market read

First‑time disclosure of Q3 results and raised guidance for a large‑cap pharma, creating a clear trading catalyst.

03

What to watch

Potential tariff impacts and debt refinancing costs could offset some of the upside.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Bausch Health Companies Inc. (NYSE:BHC) is a global diversified pharmaceutical firm with a controlling stake in Bausch + Lomb.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Bausch Health reported Q3 2026 results with 10% revenue growth and raised full-year 2026 revenue and Adjusted EBITDA guidance.

Expected impact

likely upward pressure as investors price in higher revenue and EBITDA outlook

Evidence & confidence

The company disclosed higher-than-expected revenue growth and increased full-year guidance, a material new fact for a large‑cap pharma.

Market effects

Sector

Strengthens outlook for the diversified pharma sector and may lift peers with similar exposure.

Regional

Positive for North American healthcare stocks.

Global

Limited to pharma/healthcare investors worldwide.

Counterpoint

What could challenge this read

If the guidance raise is already priced in, the stock could face a short‑term pullback.

Key entities

  • company
    Bausch Health Companies Inc.

    Issuer of the earnings release.

Read at source← All news

StoryBausch Health posts strong Q3 2026 results and lifts full‑year outlook

Also covered by

1 outlet

Related articles

OCT 28
$BHCHighAI 9/10

Why is Bausch Health stock surging today?

Bausch Health (BHC) stock rose 11.5% after reporting Q3 2026 earnings of $1.77 per share, beating estimates by $0.50, and revenue of $2.94B, exceeding expectations. The company raised full-year revenue guidance to $10.975B-$11.175B and authorized a $50M share buyback. It also redeemed $643M in debt, improving its balance sheet. The S&P 500 and Nasdaq declined 0.3% and 1.0%, respectively, on the day.

investing.com2 min
OCT 28
$BHCHighAI 8/10

BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE

Bausch Health Companies Inc. (BHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Investor Contact: Media Contact: Garen Sarafian Alexis Navratil ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (848) 264-0934 BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE • Third Quarter Consolidated Revenues of $2.

SEC EDGAR 8-K2 min